GW Pharmaceuticals to Present at the 2020 Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference
December 07, 2020 07:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization...
Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting
December 01, 2020 08:30 ET
|
GW Pharmaceuticals plc
- Meeting Highlights Include New Long-Term Data in Tuberous Sclerosis Complex - CARLSBAD, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in...
GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference
November 30, 2020 07:32 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization...
Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly
November 13, 2020 08:30 ET
|
GW Pharmaceuticals plc
- Results from analysis of three Phase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis - Treatment with nabiximols seen in this...
GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference
November 09, 2020 07:30 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization...
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress
November 03, 2020 07:30 ET
|
GW Pharmaceuticals plc
- Total revenue increased 51 percent to $137.1 million – - Epidiolex for seizures associated with TSC launched in the U.S. -- Nabiximols Phase 3 program in MS spasticity now recruiting -- Conference...
GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity
November 03, 2020 07:15 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020
October 22, 2020 10:34 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and...
Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community
October 21, 2020 08:00 ET
|
GW Pharmaceuticals plc
-- Technology provides a new way for the community to communicate and connect -- -- Launching in collaboration with patient advocacy organizations, this web-based, image-recognition technology...
GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
September 23, 2020 03:54 ET
|
GW Pharmaceuticals plc
LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved...